Why is HCA Healthcare stock surging today?

HCA Healthcare stock surged 3.2% in pre-open trading after the Nashville-based hospital operator delivered a third-quarter earnings report that comfortably exceeded the lowered expectations Wall Street had set heading into the print.

The company posted diluted EPS of $7.27, a 4.5% increase year-over-year and a significant beat against the consensus estimate of approximately $6.65, while quarterly revenues of $19.849 billion grew 3.6% from the prior-year period and came in ahead of the roughly $19.33 billion analysts had projected.

Operational metrics reinforced the headline numbers: same-facility admissions rose 2.7% and same-facility equivalent admissions climbed 3.0%, signaling that patient volume trends remained resilient even as a shift toward uninsured patients weighed on the payer mix.

Crucially, management updated its full-year 2026 outlook, indicating it now expects operating results to fall in the upper half of its previously stated guidance range — a forward-looking signal that carries particular weight given the negative EPS estimate revisions analysts had made over the preceding 90 days.

Adjusted EBITDA reached $3.918 billion for the quarter, and cash flows from operations totaled $4.461 billion.

The earnings beat arrives against a backdrop of cautious but broadly supportive analyst sentiment. Twenty-two analysts tracked by Benzinga held a Buy consensus on HCA heading into the report, with an average price target of $477 — a level the stock is now approaching in pre-market.

The broader U.S. equity market is providing a mild tailwind, with the S&P 500 up 0.3%, the Dow Jones up 0.2%, and the Nasdaq up 0.5%, as investors navigate a busy earnings week for the index.

Taken together, a decisive EPS beat, better-than-expected revenue growth, solid volume trends, and an upward guidance revision combined to reset investor expectations sharply higher.

The move also reflects a relief rally: with analyst estimates having drifted lower for months amid Medicaid and payer-mix concerns, the actual results demonstrated that HCA’s underlying business proved more durable than feared, giving bulls a clear catalyst to push the stock toward its average analyst price target.